Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | GABRA1 | P14867 | 1/20 | 0.48 |
| ▸ | GABRB2 | P47870 | 1/20 | 0.48 |
| ▸ | ERN1 | O75460 | 6/20 | 0.43 |
| ▸ | TLR2 | O60603 | 1/20 | 0.41 |
| ▸ | TLR1 | Q15399 | 1/20 | 0.41 |
| ▸ | TLR6 | Q9Y2C9 | 1/20 | 0.41 |
| ▸ | SRC | P12931 | 1/20 | 0.38 |
| ▸ | TYR | P14679 | 2/20 | 0.37 |
| ▸ | TRIM24 | O15164 | 2/20 | 0.37 |
| ▸ | TRIM33 | Q9UPN9 | 2/20 | 0.37 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.36 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1981756 | 0.83 | ERN1 (0.41) | GABRA1GABRB2ERN1TLR2TLR1 | |
| SCHEMBL28775677 | 0.83 | GABRA1 (0.45) | GABRA1GABRB2ERN1TLR2TLR1 | |
| SCHEMBL28807252 | 0.83 | TYR (0.45) | ERN1TYR | |
| SCHEMBL27157043 | 0.82 | ERN1 (0.44) | GABRA1GABRB2ERN1TLR2TLR1 | |
| SCHEMBL29607733 | 0.81 | GABRA1 (0.64) | GABRA1GABRB2ERN1TLR2TLR1 | |
| SCHEMBL1527079 | 0.81 | GABRA1 (0.64) | GABRA1GABRB2ERN1TLR2TLR1 | |
| SCHEMBL45861 | 0.81 | GABRA1 (0.68) | GABRA1GABRB2TYR | |
| SCHEMBL17541404 | 0.81 | ERN1 (0.59) | ERN1TLR2TLR1TLR6TYR | |
| SCHEMBL31450219 | 0.81 | ERN1 (0.59) | ERN1TLR2TLR1TLR6TYR | |
| SCHEMBL6907532 | 0.78 | GABRA1 (0.48) | GABRA1GABRB2ERN1ALDH1A1L3MBTL1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 10 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8198302-B2 | Anticancer agent having a quinone, quinone prodrug, catechol or catechol prodrug moiety; free of combretastatin A-1 | OXIGENE, INC. (US) | 2012-06-12 | — | — | US | disclosed |
| US-8198302-B2 | Anticancer agent having a quinone, quinone prodrug, catechol or catechol prodrug moiety; free of combretastatin A-1 | OXIGENE, INC. (US) | 2012-06-12 | — | — | US | disclosed |
| US-8198302-B2 | Anticancer agent having a quinone, quinone prodrug, catechol or catechol prodrug moiety; free of combretastatin A-1 | OXIGENE, INC. (US) | 2012-06-12 | — | — | US | disclosed |
| EP-1601348-A4 | COMPOSITIONS AND METHODS WITH ENHANCED THERAPEUTIC ACTIVITY | OXIGENE INC (US) | 2008-12-10 | — | — | EP | disclosed |
| EP-1601348-A2 | COMPOSITIONS AND METHODS WITH ENHANCED THERAPEUTIC ACTIVITY | OXIGENE, INC. (US) | 2005-12-07 | — | — | EP | disclosed |
| US-20040242696-A1 | Compositions and methods with enhanced therapeutic activity | MATEON THERAPEUTICS, INC. | 2004-12-02 | — | — | US | disclosed |
| WO-2004078126-A2 | COMPOSITIONS AND METHODS WITH ENHANCED THERAPEUTIC ACTIVITY | OXIGENE, INC. (US) | 2004-09-16 | — | — | WO | disclosed |
| EP-0579412-B1 | 1,2,4-trioxygenated benzene derivatives useful as a leukotriene antagonists | LILLY CO ELI (US) | 1998-10-07 | — | — | EP | disclosed |
| US-5352690-A | For asthma, allergies | ELI LILLY AND COMPANY (US) | 1994-10-04 | — | — | US | disclosed |
| EP-0579412-A1 | 1,2,4-trioxygenated benzene derivatives useful as a leukotriene antagonists | ELI LILLY AND COMPANY (US) | 1994-01-19 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20040242696-A1 | Compositions and methods with enhanced therapeutic activity | NQO1, MKI67, COMT | GABRA1 4558/4885GABRB2 4404/4885ERN1 3895/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.